title: Results of the phase II EORTC study comparing paclitaxel/cisplatin with teniposide/cisplatin in patients with non-small cell lung cancer. EORTC Lung Cancer Cooperative Group.
abstract: Toxicity and response rates are evaluated in a randomized phase II study comparing paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ)/cisplatin with teniposide/cisplatin in the treatment of non-small cell lung cancer to decide whether this study should continue as a phase III trial. A response was seen in 26% (10 of 38) of the patients receiving teniposide/cisplatin and in 40% (14 of 35) of those receiving paclitaxel/cisplatin. Overall, evidence of toxicity was more severe in the cisplatin/teniposide group, especially with regard to myelotoxicity. Grade 4 neutropenia was seen in 66% of patients receiving teniposide compared with 29% of those treated with paclitaxel/cisplatin. The study is to continue as a phase III trial, with 150 patients expected to participate in each treatment group.
authors.affiliation: Department of Pulmonary Diseases, Free University Hospital, Amsterdam, The Netherlands.
authors.forename: P E
authors.initials: PE
authors.lastname: Postmus
authors.forename: G
authors.initials: G
authors.lastname: Giaccone
authors.forename: C
authors.initials: C
authors.lastname: Debruyne
authors.forename: T
authors.initials: T
authors.lastname: Sahmoud
authors.forename: T A
authors.initials: TA
authors.lastname: Splinter
authors.forename: N
authors.initials: N
authors.lastname: van Zandwijk
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D013713:Teniposide / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D013713:Teniposide; D017239:Paclitaxel; D002945:Cisplatin